← Back to headlines
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant for SAB-142 Assessment
SAB Biotherapeutics (SABS) and Breakthrough T1D have been awarded a research grant for the assessment of SAB-142. This funding will support further study into the therapeutic potential of SAB-142.
15 Jul, 15:43 — 15 Jul, 15:43
Sources
Showing 1 of 1 sources
Related Stories
Nvidia’s AI Optimism Drives Global Market Gains Amid Macro Caution
41m ago
US in Talks to Secure Major Stake in Venezuelan Oil Reserves
50m ago
FDA Approves Updated Pfizer-BioNTech and Moderna COVID Vaccines for 2026-27 Season
55m ago
Andy Burnham Launches Crackdown on Rogue Bailiffs and Unregulated Builders
1h ago